Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 18;26(8):3828.
doi: 10.3390/ijms26083828.

Current Treatment Paradigms for Advanced Melanoma with Brain Metastases

Affiliations
Review

Current Treatment Paradigms for Advanced Melanoma with Brain Metastases

Elisabetta Bonzano et al. Int J Mol Sci. .

Abstract

The therapeutic management of melanoma brain metastases has undergone a profound revolution during recent decades. Optimal integration of systemic therapies with local treatments seems to represent the strategy to pursue in order to maximize clinical outcomes, stressing the need for real multidisciplinary care in this setting of patients. However, the current approach in the clinics does not necessarily reflect what the current guidelines state, and several pending issues are present, from the ideal therapeutic sequence between stereotactic radiosurgery (SRS) and drug administration to the current role of surgery and whole brain radiotherapy (WBRT), all of which need to be addressed. This narrative review aims to provide practical help for navigating the current controversies, with an eye towards possible future advancements in the field, which could help to obtain a comprehensive molecular characterization of the tumor and a more personalized patient-centered therapeutic approach.

Keywords: brain metastases; immunotherapy; melanoma; multidisciplinary treatment; radiotherapy; stereotactic radiosurgery; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

References

    1. Arnold M., Singh D., Laversanne M., Vignat J., Vaccarella S., Meheus F., Cust A.E., de Vries E., Whiteman D.C., Bray F. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022;158:495–503. doi: 10.1001/jamadermatol.2022.0160. - DOI - PMC - PubMed
    1. Kim H.J., Kim Y.H. Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances. Int. J. Mol. Sci. 2024;25:2984. doi: 10.3390/ijms25052984. - DOI - PMC - PubMed
    1. Lonser R.R., Song D.K., Klapper J., Hagan M., Auh S., Kerr P.B., Citrin D.E., Heiss J.D., Camphausen K., Rosenberg S.A. Surgical management of melanoma brain metastases in patients treated with immunotherapy. J. Neurosurg. 2011;115:30–36. doi: 10.3171/2011.3.JNS091107. - DOI - PMC - PubMed
    1. Bedikian A.Y., Wei C., Detry M., Kim K.B., Papadopoulos N.E., Hwu W.-J., Homsi J., Davies M., McIntyre S.M., Hwu P. Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma. Am. J. Clin. Oncol. 2011;34:603–610. doi: 10.1097/COC.0b013e3181f9456a. - DOI - PubMed
    1. Eichler A.F., Chung E., Kodack D.P., Loeffler J.S., Fukumura D., Jain R.K. The biology of brain metastases—Translation to new therapies. Nat. Rev. Clin. Oncol. 2011;8:344–356. doi: 10.1038/nrclinonc.2011.58. - DOI - PMC - PubMed

LinkOut - more resources